Subsequent event risk in individuals with established coronary heart disease: design and rationale of the GENIUS-CHD consortium

BACKGROUND: The Genetics of Subsequent Coronary Heart Disease (GENIUS-CHD) consortium was established to facilitate discovery and validation of genetic variants and biomarkers for risk of subsequent CHD events, in individuals with established CHD. - METHODS: The consortium currently includes 57 stud...

Full description

Saved in:
Bibliographic Details
Main Authors: Patel, Riyaz (Author) , Breitling, Lutz Philipp (Author) , Delgado Gonzales de Kleber, Graciela (Author) , Kleber, Marcus E. (Author) , Mons, Ute (Author) , Brenner, Hermann (Author) , März, Winfried (Author)
Format: Article (Journal)
Language:English
Published: 21 March 2019
In: Circulation. Genomic and precision medicine
Year: 2019, Volume: 12, Issue: 4
ISSN:2574-8300
DOI:10.1161/CIRCGEN.119.002470
Online Access:Verlag, Pay-per-use, Volltext: http://dx.doi.org/10.1161/CIRCGEN.119.002470
Get full text
Author Notes:Riyaz S. Patel, Vinicius Tragante, Amand F. Schmidt, Lutz P. Breitling, Graciela Delgado, Marcus Kleber, Ute Mons, Hermann Brenner, Winfried März et al
Description
Summary:BACKGROUND: The Genetics of Subsequent Coronary Heart Disease (GENIUS-CHD) consortium was established to facilitate discovery and validation of genetic variants and biomarkers for risk of subsequent CHD events, in individuals with established CHD. - METHODS: The consortium currently includes 57 studies from 18 countries, recruiting 185 614 participants with either acute coronary syndrome, stable CHD, or a mixture of both at baseline. All studies collected biological samples and followed-up study participants prospectively for subsequent events. - RESULTS: Enrollment into the individual studies took place between 1985 to present day with a duration of follow-up ranging from 9 months to 15 years. Within each study, participants with CHD are predominantly of self-reported European descent (38%-100%), mostly male (44%-91%) with mean ages at recruitment ranging from 40 to 75 years. Initial feasibility analyses, using a federated analysis approach, yielded expected associations between age (hazard ratio, 1.15; 95% CI, 1.14-1.16) per 5-year increase, male sex (hazard ratio, 1.17; 95% CI, 1.13-1.21) and smoking (hazard ratio, 1.43; 95% CI, 1.35-1.51) with risk of subsequent CHD death or myocardial infarction and differing associations with other individual and composite cardiovascular endpoints. - CONCLUSIONS: GENIUS-CHD is a global collaboration seeking to elucidate genetic and nongenetic determinants of subsequent event risk in individuals with established CHD, to improve residual risk prediction and identify novel drug targets for secondary prevention. Initial analyses demonstrate the feasibility and reliability of a federated analysis approach. The consortium now plans to initiate and test novel hypotheses as well as supporting replication and validation analyses for other investigators.
Item Description:Gesehen am 14.08.2019
Physical Description:Online Resource
ISSN:2574-8300
DOI:10.1161/CIRCGEN.119.002470